These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34012588)

  • 1. EpCAM expression in esophageal cancer and its correlation with immunotherapy of solitomab.
    Yu L; Guo QM; Wang Y; Xu Y; Liu L; Zhang XT
    J Thorac Dis; 2021 Apr; 13(4):2404-2413. PubMed ID: 34012588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
    English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
    Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.
    Kebenko M; Goebeler ME; Wolf M; Hasenburg A; Seggewiss-Bernhardt R; Ritter B; Rautenberg B; Atanackovic D; Kratzer A; Rottman JB; Friedrich M; Vieser E; Elm S; Patzak I; Wessiepe D; Stienen S; Fiedler W
    Oncoimmunology; 2018; 7(8):e1450710. PubMed ID: 30221040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
    Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
    Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells.
    Chen Y; Liu L; Li J; Du Y; Wang J; Liu J
    Pathol Res Pract; 2019 Mar; 215(3):470-477. PubMed ID: 30606658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy.
    Mitra M; Kandalam M; Harilal A; Verma RS; Krishnan UM; Swaminathan S; Krishnakumar S
    Mol Vis; 2012; 18():290-308. PubMed ID: 22328825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Overexpression of Smac gene enhanced chemotherapeutic sensitivity of esophageal cancer cell line Eca109 to cisplatin].
    Du N; Yang B; Hu LJ; Zhao Y; Sun X; Guo ZW; Ren H
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Apr; 28(4):344-6. PubMed ID: 22482401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells.
    Mitra M; Misra R; Harilal A; Sahoo SK; Krishnakumar S
    Mol Vis; 2011; 17():2724-37. PubMed ID: 22065926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esophageal cancer tumorspheres involve cancer stem-like populations with elevated aldehyde dehydrogenase enzymatic activity.
    Zhang G; Ma L; Xie YK; Miao XB; Jin C
    Mol Med Rep; 2012 Sep; 6(3):519-24. PubMed ID: 22684859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Silasi DA; Rüttinger D; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2010 Dec; 203(6):582.e1-7. PubMed ID: 20870202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCG2 gene amplification and expression in esophageal cancer cells with acquired adriamycin resistance.
    Liu L; Zuo LF; Guo JW
    Mol Med Rep; 2014 Apr; 9(4):1299-304. PubMed ID: 24535197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of
    Wang YX; Zhang CQ; Han F
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Jan; 51(1):24-29. PubMed ID: 31950785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limonoid compounds from Xylocarpus granatum and their anticancer activity against esophageal cancer cells.
    Jing L; Feng L; Zhou Z; Shi S; Deng R; Wang Z; Liu Y
    Thorac Cancer; 2020 Jul; 11(7):1817-1826. PubMed ID: 32449599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
    Cioffi M; Dorado J; Baeuerle PA; Heeschen C
    Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Smac in combination with cisplatin on esophageal cancer cell line ECA109.
    Hou L; Chen K; Hao Y; Zhao Y; Sun Q; Zhao X; Peng C
    Int J Clin Exp Med; 2015; 8(10):18506-11. PubMed ID: 26770460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
    El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
    Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.